SARS-CoV-2与糖尿病:大流行后的再评估
本文对COVID-19与糖尿病交叉领域的临床与实验文献进行大流行后综述,总结SARS-CoV-2感染胰腺和外周胰岛素敏感组织等病理生理机制,回顾COVID-19与新发1型和2型糖尿病关联的关键荟萃分析,并讨论长新冠与糖尿病的关系及疫苗接种对感染后糖尿病风险的影响。
要点
- 糖尿病是重症COVID-19和死亡的最强预测因素之一。
- COVID-19感染后新发糖尿病报告提示可能存在双向关系。
- 需关注长新冠与糖尿病的关系及疫苗接种对糖尿病风险的影响。
核心结论
- 糖尿病是重症COVID-19结局和死亡的最强预测因素之一,被置于早期风险分层和治疗框架的中心。
主要发现
- 早期疫情期间,糖尿病成为重症COVID-19结局和死亡的最强预测因素之一。
- COVID-19感染后新发糖尿病的报告提示SARS-CoV-2感染与糖尿病之间可能存在双向关系。
- 综述总结了SARS-CoV-2感染对胰腺和外周胰岛素敏感组织影响的病理生理机制。
- 综述回顾了评估COVID-19与新发1型和2型糖尿病关联的关键荟萃分析及其流行病学研究的优缺点。
- 综述讨论了长新冠与糖尿病的新兴关系以及疫苗接种对SARS-CoV-2感染后糖尿病风险的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic was a dynamic and often confusing period for clinical and biomedical research. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread globally, knowledge accumulated rapidly through publications that were frequently based on preliminary or sometimes conflicting evidence, yet these papers played a critical role in shaping evolving medical, research and societal responses. Early in the pandemic, diabetes emerged as one of the strongest predictors of severe COVID-19 outcomes and mortality, placing it at the centre of early risk-stratification and therapeutic frameworks and prompting urgent efforts to understand the biological basis of these associations. As the pandemic progressed, reports of new-onset diabetes following COVID-19 infection raised the possibility of a bidirectional relationship between SARS-CoV-2 infection and diabetes. In this review, we provide a post-pandemic reappraisal of the clinical and experimental literature examining the intersection of COVID-19 and diabetes. We summarise proposed pathophysiological mechanisms, including the effects of SARS-CoV-2 infection in the pancreas and on peripheral insulin-sensitive tissues. We review key meta-analyses assessing the association between COVID-19 and incident type 1 and type 2 diabetes and highlight strengths and weaknesses of the epidemiologic studies underpinning these findings. We highlight the highest-quality evidence from prospective cohorts, as well as relevant clinical trials and registry-based studies that emerged from this collective experience. We discuss emerging relationships between long COVID and diabetes and the effect of vaccination on diabetes risk following SARS-CoV-2 infection. Finally, we identify critical knowledge gaps and outline priorities for ongoing and future studies needed to resolve remaining uncertainties.
引用
- Said N, Jones I, Anderson-Baucum EK, et al. SARS-CoV-2 and diabetes: a post-pandemic reappraisal. Diabetologia. 2026. PMID: 42362970. doi:10.1007/s00125-026-06785-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。